for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innoviva Inc

INVA.OQ

Latest Trade

13.99USD

Change

0.06(+0.43%)

Volume

264,682

Today's Range

13.81

 - 

14.15

52 Week Range

7.58

 - 

15.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.93
Open
14.09
Volume
264,682
3M AVG Volume
15.26
Today's High
14.15
Today's Low
13.81
52 Week High
15.60
52 Week Low
7.58
Shares Out (MIL)
101.32
Market Cap (MIL)
1,417.47
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q2 2020 Innoviva Inc Earnings Release

Latest Developments

More

Innoviva Names Pavel Raifeld As Chief Executive Officer

Innoviva Reports First Quarter 2020 Financial Results

GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innoviva Inc

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry

Biotechnology & Drugs

Contact Info

2000 Sierra Point Pkwy Ste 500

BRISBANE, CA

94005-1830

United States

+1.650.2389600

https://www.inva.com/

Executive Leadership

Odysseas D. Kostas

Independent Chairman of the Board

Pavel Raifeld

Chief Executive Officer

Marianne Y. Zhen

Chief Accounting Officer

George W. Bickerstaff

Independent Director

Mark A. DiPaolo

Independent Director

Key Stats

4.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.3K

2019

0.3K

2020(E)

0.2K
EPS (USD)

2017

1.170

2018

1.750

2019

1.430
Price To Earnings (TTM)
8.35
Price To Sales (TTM)
4.98
Price To Book (MRQ)
3.73
Price To Cash Flow (TTM)
5.82
Total Debt To Equity (MRQ)
99.90
LT Debt To Equity (MRQ)
99.90
Return on Investment (TTM)
34.48
Return on Equity (TTM)
33.37

Latest News

Latest News

BRIEF-Theravance Biopharma Says Received From Innoviva Draft TRC Quarterly Financial Plan

* THERAVANCE BIOPHARMA - ON JUNE 1, 2020 RECEIVED FROM INNOVIVA DRAFT TRC QTRLY FINANCIAL PLAN FOR QUARTER ENDING SEPT 30, 2020

BRIEF-Innoviva Names Pavel Raifeld As Chief Executive Officer

* INNOVIVA INC - APPOINTMENT OF PAVEL RAIFELD AS CEO EFFECTIVE MAY 20, 2020

BRIEF-Innoviva Reports First Quarter 2020 Financial Results

* QTRLY EARNINGS PER SHARE $0.59 Source text for Eikon: Further company coverage:

BRIEF-Innoviva, Inc Reports 19.996% Stake In Entasis Therapeutics Holdings As Of April 22

* INNOVIVA, INC REPORTS 19.996% STAKE IN ENTASIS THERAPEUTICS HOLDINGS AS OF APRIL 22 - SEC FILING Source text: [https://bit.ly/2zoeuFf] (Reuters.Briefs@thomsonreuters.com)

BRIEF-Entasis Therapeutics Entered Into Securities Purchase Agreement With Innoviva

* ENTASIS THERAPEUTICS- ON APR 12, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT WITH INNOVIVA

BRIEF-Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only

* INNOVIVA INC - CO'S 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD IN VIRTUAL MEETING FORMAT ONLY Source text for Eikon: Further company coverage:

BRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive Officer

* INNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER Source text for Eikon: Further company coverage:

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

BRIEF-Innoviva prices offering of $175 mln of 2.50 pct convertible senior notes

* Innoviva Inc. prices offering of $175 million of 2.50 pct convertible senior notes Source text for Eikon: Further company coverage:

BRIEF-Innoviva proposes $175 mln offering of convertible senior notes

* Innoviva announces proposed offering of $175 million of convertible senior notes

BRIEF-Innoviva Q2 adjusted earnings per share $0.35

* Innoviva reports strong second quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up